Tag Archives: Philadelphia

Sprycel (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Print this page PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel ® (dasatinib) tablets to include the treatment of pediatric patients one year of age and older with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy.1 Sprycel… Read More »

Children’s Hospital of Philadelphia victimized twice by phishing attacks

Children’s Hospital of Philadelphia has reported two data breaches that occurred in August and September of 2018. The hospital on August 24 discovered that hacker had accessed a physician’s email account on August 23 via a phishing attack. A second breach found on September 6 revealed unauthorized access to an additional email account on August… Read More »